These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35165826)

  • 1. Generation of NPHP1 knockout human pluripotent stem cells by a practical biallelic gene deletion strategy using CRISPR/Cas9 and ssODN.
    Nakano Y; Susa K; Yanagi T; Hiraoka Y; Suzuki T; Mori T; Ando F; Mandai S; Fujiki T; Rai T; Uchida S; Sohara E
    In Vitro Cell Dev Biol Anim; 2022 Feb; 58(2):85-95. PubMed ID: 35165826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of induced pluripotent stem cell line carrying frameshift variants in NPHP1 (UCSFi001-A-68) using CRISPR/Cas9.
    Dyke E; Bijnagte-Schoenmaker C; Wu KM; Oudakker A; Roepman R; Nadif Kasri N
    Stem Cell Res; 2023 Apr; 68():103053. PubMed ID: 36842376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
    Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
    Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient gene correction of an aberrant splice site in β-thalassaemia iPSCs by CRISPR/Cas9 and single-strand oligodeoxynucleotides.
    Xiong Z; Xie Y; Yang Y; Xue Y; Wang D; Lin S; Chen D; Lu D; He L; Song B; Yang Y; Sun X
    J Cell Mol Med; 2019 Dec; 23(12):8046-8057. PubMed ID: 31631510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
    Yumlu S; Bashir S; Stumm J; Kühn R
    Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9 Genome Editing of Human-Induced Pluripotent Stem Cells Followed by Granulocytic Differentiation.
    Dannenmann B; Nasri M; Welte K; Skokowa J
    Methods Mol Biol; 2020; 2115():471-483. PubMed ID: 32006418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome Editing of Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes to Model Genetic Ocular Diseases.
    Getachew H; Chinchilla B; Fernandez-Godino R
    Methods Mol Biol; 2022; 2549():321-334. PubMed ID: 34128206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing.
    Guo T; Feng YL; Xiao JJ; Liu Q; Sun XN; Xiang JF; Kong N; Liu SC; Chen GQ; Wang Y; Dong MM; Cai Z; Lin H; Cai XJ; Xie AY
    Genome Biol; 2018 Oct; 19(1):170. PubMed ID: 30340517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trichostatin A for Efficient CRISPR-Cas9 Gene Editing of Human Pluripotent Stem Cells.
    Molugu K; Khajanchi N; Lazzarotto CR; Tsai SQ; Saha K
    CRISPR J; 2023 Oct; 6(5):473-485. PubMed ID: 37676985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression.
    Li XL; Li GH; Fu J; Fu YW; Zhang L; Chen W; Arakaki C; Zhang JP; Wen W; Zhao M; Chen WV; Botimer GD; Baylink D; Aranda L; Choi H; Bechar R; Talbot P; Sun CK; Cheng T; Zhang XB
    Nucleic Acids Res; 2018 Nov; 46(19):10195-10215. PubMed ID: 30239926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
    Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
    Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells.
    Prat F; Toutain J; Boutin J; Amintas S; Cullot G; Lalanne M; Lamrissi-Garcia I; Moranvillier I; Richard E; Blouin JM; Dabernat S; Moreau-Gaudry F; Bedel A
    Stem Cell Reports; 2020 Sep; 15(3):677-693. PubMed ID: 32795423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.
    Simkin D; Papakis V; Bustos BI; Ambrosi CM; Ryan SJ; Baru V; Williams LA; Dempsey GT; McManus OB; Landers JE; Lubbe SJ; George AL; Kiskinis E
    Stem Cell Reports; 2022 Apr; 17(4):993-1008. PubMed ID: 35276091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice.
    Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X
    Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9-Based Genome Editing of Human Induced Pluripotent Stem Cells.
    Giacalone JC; Sharma TP; Burnight ER; Fingert JF; Mullins RF; Stone EM; Tucker BA
    Curr Protoc Stem Cell Biol; 2018 Feb; 44():5B.7.1-5B.7.22. PubMed ID: 29512106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and Genetic Correction of USH2A c.2299delG Mutation in Patient-Derived Induced Pluripotent Stem Cells.
    Liu X; Lillywhite J; Zhu W; Huang Z; Clark AM; Gosstola N; Maguire CT; Dykxhoorn D; Chen ZY; Yang J
    Genes (Basel); 2021 May; 12(6):. PubMed ID: 34070435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.